ArticleArquivos de neuro-psiquiatria2025
Assessing female sexual dysfunction in patients with relapsing-remitting multiple sclerosis.
Article in Arquivos de neuro-psiquiatria, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple sclerosis (MS) affects mainly young people of reproductive age with significant lifelong repercussions, among which sexual dysfunction (SD) is one of the most neglected during routine clinical care.
objectiveTo evaluate SD in female patients diagnosed with relapsing-remitting MS (RRMS).
methodsThis cross-sectional analytic study was performed at the Santa Casa de São Paulo Hospital, Faculdade de Ciências Médicas, São Paulo, Brazil, between November 2020 and March 2022. The sample included 80 female patients diagnosed with RRMS and 106 healthy controls. Questionnaires probing sexual dysfunction (the Multiple Sclerosis Intimacy and Sexuality Questionnaire - MSISQ-19 and the Female Sexual Function Index - FSFI) and depression and anxiety (the Hospital Anxiety and Depression Scale - HADS, the Beck Depression Inventory - BDI; and the Beck Anxiety Inventory - BAI) were applied.
resultsA high prevalence of SD in both groups (43.4% and 38.8% for the RRMS and control groups, respectively) was identified by the FSFI analysis. A statistically higher prevalence (56.3%) of sexual dysfunction was detected in RRMS patients when using the MSISQ-19 tool to assess sexuality in this population compared with the FSFI scale (
conclusionA high prevalence of SD was found in both MS patients and healthy controls as measured by the FSFI. However, the specific tool (MSISQ-19) revealed a higher prevalence of SD in MS patients. Thus, the use of MSISQ-19 for the diagnosis and management of SD in this patient group is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.